首页> 外文OA文献 >Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.
【2h】

Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

机译:均抑制因子VIII促凝活性的鼠单克隆抗因子VIII抗体和人抗因子VIII同种抗体的结合区定位于因子VIII重链的苏氨酸351-丝氨酸365的氨基酸残基。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have localized the binding region of a previously described monoclonal anti-factor VIII (FVIII) inhibitory antibody (C5) to amino acid residues Thr351-Ser365 of the thrombin-generated 54-kD fragment of the heavy chain of FVIII. Synthetic FVIII peptides were examined for the ability to competitively inhibit the binding of C5 to FVIII in an ELISA system. The synthetic FVIII peptide Thr351-Ser365 blocked C5 binding to FVIII in a dose-dependent manner in this system. Two other synthetic FVIII peptides, Asn340-Glu354 and Glu342-Asp356, which partially overlapped Thr351-Ser365, also blocked C5 binding to FVIII. Blocking of C5 binding with these peptides, however, required much greater concentrations (greater than 100 times stronger) than that required for Thr351-Ser365. The Thr351-Ser365 peptide also neutralized the FVIII inhibitory activity of C5 in plasma. A human FVIII inhibitor (anti-FVIII heavy chain alloantibody) was also partially neutralized by Thr351-Ser365. Thr351-Ser365 lies between a thrombin cleavage site (Arg372) and an activated protein C cleavage site (Arg336) and may be at or near a region of functional importance in the expression of FVIII procoagulant activity.
机译:我们已经将先前描述的单克隆抗因子VIII(FVIII)抑制性抗体(C5)的结合区域定位在凝血酶产生的FVIII重链54-kD片段的氨基酸残基Thr351-Ser365上。在ELISA系统中,检查了合成的FVIII肽竞争性抑制C5与FVIII结合的能力。在该系统中,合成的FVIII肽Thr351-Ser365以剂量依赖的方式阻断了C5与FVIII的结合。与Thr351-Ser365部分重叠的另两种合成FVIII肽Asn340-Glu354和Glu342-Asp356也阻断了C5与FVIII的结合。但是,与这些肽阻断C5结合需要的浓度要比Thr351-Ser365高得多(大于100倍)。 Thr351-Ser365肽还中和了血浆中C5的FVIII抑制活性。人FVIII抑制剂(抗FVIII重链同种抗体)也被Thr351-Ser365中和。 Thr351-Ser365位于凝血酶切割位点(Arg372)和活化的蛋白C切割位点(Arg336)之间,可能在FVIII促凝血活性表达中具有功能重要性的区域或附近。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号